Dabrafenib_Mesylate_LCMS_19555_MedChemExpress

细胞色素氧化酶染色液(DAB法)使用说明书货号：G2410规格：4×50ml有效期：-20℃，6个月。

产品组成：产品名称规格保存试剂(A):CO清除液2×50ml4℃避光试剂(B):DAB 孵育液B1:DAB染色液45ml-20℃避光B2:DAB增强剂5ml-20℃避光B3:DAB反应液100μl-20℃避光按B1:B2:B3=9000:1000:3混合，即为DAB孵育液，即配即用。

试剂(C):苏木素染色液50ml4℃避光试剂(D):CO对照液1ml RT产品说明：细胞色素氧化酶(Cytochrome Oxidase，CO)被认为是线粒体膜固有的酶，在含有大量线粒体的细胞(如心肌、肾小管上皮以及胃壁细胞、肝细胞)内都具有高度活性。

此酶活性往往作为细胞内氧化代谢的指标，亦作为线粒体的标志酶之一。

细胞色素氧化酶染色液(DAB法)染色原理是细胞色素氧化酶催化DAB使其侧链的氨基氧化，进行反复的氧化性聚合和氧化性环化形成不溶性的棕色Phenazine聚合物。

此酶对固定剂敏感，故须用新鲜切片。

自备材料：1、恒温培养箱2、光学显微镜操作步骤(仅供参考)：1、冰冻切片，厚6μm，不固定。

2、滴加CO清除液于切片上，铺满整个样品表面。

3、切片入DAB孵育液中，37℃避光孵育45～60min。

第1页，共2页4、移去切片上的染色液，滴加CO清除液于切片上，铺满整个样品表面。

5、蒸馏水稍洗3～5s。

6、(可选)滴加苏木素染色液浅染细胞核3～5min。

7、流水冲洗10min。

常规脱蜡透明，中性树胶封固。

染色结果：CO酶活性部位棕色心肌、肾小管上皮内颗粒(线粒体)蓝色阴性对照(可选)：取新鲜配制好的DAB孵育液，按DAB孵育液:CO对照液=50:1的比例混合，即为CO对照工作液。

相同切片入CO对照工作液，室温孵育30～60min，其余同上，呈阴性反应。

注意事项：1、本染色液适用于冰冻切片，同时应减少切片在室温暴露的时间。

恶性胸膜间皮瘤靶向治疗的研究进展傅芬;张扬;沈红【期刊名称】《中国肺癌杂志》【年(卷),期】2024(27)5【摘要】恶性胸膜间皮瘤(malignant pleural mesothelioma, MPM)是侵袭性极强的罕见胸膜表面恶性肿瘤,危险因素包括吸入石棉、遗传因素、基因突变等。

现有的化疗、抗血管生成治疗、免疫治疗的效果均不佳,患者的生存期极短。

亟需寻找治疗MPM的潜在靶点,目前发现有基因突变靶点如BRCA1相关蛋白1(BRCA associated protein1, BAP1)和细胞周期蛋白依赖性激酶抑制剂2A(cyclin-dependent kinase 2A, CDKN2A)等;表观遗传靶点如组蛋白赖氨酸去甲基酶4A[lysine (K)-specific demethylase 4A, KDM4A]和赖氨酸特异性去甲基酶1(lysine-specific demethylase1, LSD1)等;信号蛋白靶点如葡萄糖调节蛋白78(glucose-regulated protein 78, GRP78)及信号转导和转录激活因子3(signal transducer and activator of transcription 3, STAT3)等。

迄今为止,可查询的临床试验有组蛋白甲基转移酶抑制剂Tazemetostat、多聚ADP-核糖聚合酶[poly (ADP-ribose) polymerase, PARP]抑制剂Rucaparib和细胞周期蛋白依赖性激酶4/6(cyclin-dependent kinases 4 and 6, CDK4/6)抑制剂Abemaciclib的II期临床试验,以及靶向间皮素的嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immunotherapy, CAR-T)细胞胸腔注射、TEA结构域家族成员(TEA domain family member, TEAD)抑制剂VT3989和IK-930的I期临床试验,显示出一定的临床疗效。

生物技术进展 2023 年 第 13 卷 第 4 期 596 ~ 603Current Biotechnology ISSN 2095‑2341研究论文Articles重组贻贝粘蛋白的表征及功效评价李敏 ， 魏文培 ， 乔莎 ， 郝东 ， 周浩 ， 赵硕文 ， 张立峰 ， 侯增淼 *西安德诺海思医疗科技有限公司，西安 710000摘要：为了推进重组贻贝粘蛋白在医疗、化妆品领域的应用，对大肠杆菌规模化发酵及纯化生产获得的重组贻贝粘蛋白进行了表征及功效评价。

经Edman 降解法、基质辅助激光解吸电离飞行时间质谱、PITC 法、非还原型SDS -聚丙烯酰胺凝胶电泳法、凝胶法、改良的Arnow 法对重组贻贝粘蛋白进行氨基酸N 端测序、相对分子量分析、氨基酸组成分析、蛋白纯度分析、内毒素含量测定、多巴含量测定；通过细胞迁移、斑马鱼尾鳍修复效果对重组贻贝粘蛋白进行功效评价。

结果显示，获得的重组贻贝粘蛋白与理论的一级结构一致，蛋白纯度达95%以上，内毒素<10 EU ·mg -1,多巴含量大于5%；重组贻贝粘蛋白浓度为60 μg ·mL -1时能够显著促进细胞增殖的活性（P <0.01）；斑马鱼尾鳍面积样品组与模型对照组相比极显著增加（P <0.001）。

研究结果表明，重组贻贝粘蛋白具有显著的促细胞迁移和修复愈合的功效，具备作为生物医学材料的潜质。

关键词：贻贝粘蛋白；基因重组；生物材料；表征；功效评价DOI ：10.19586/j.2095­2341.2023.0021 中图分类号：S985.3+1 文献标志码：ACharacterization and Efficacy Evaluation of Recombinant Mussel Adhesive ProteinLI Min ， WEI Wenpei ， QIAO Sha ， HAO Dong ， ZHOU Hao ， ZHAO Shuowen ， ZHANG Lifeng ，HOU Zengmiao *Xi'an DeNovo Hith Medical Technology Co.， Ltd ， Xi'an 710000， ChinaAbstract ：In order to promote the application of recombinant mussel adhesive protein in the medical and cosmetics field ， the recombi⁃nant mussel adhesive protein obtained from scale fermentation and purification of Escherichia coli was characterized and its efficacy was evaluated. Amino acid N -terminal sequencing ， relative molecular weight analysis ， amino acid composition analysis ， protein purityanalysis ， endotoxin content ， dihydroxyphenylalanine （DOPA ） content of recombinant mussel adhesive protein were determined by the following methods ： Edman degradation ， matrix -assisted laser desorption ionization time -of -flight mass spectrometry （MALDI -TOF -MS ）， phenyl -isothiocyanate （PITC ）， nonreductive SDS -polyacrylamide gel electrophoresis （SDS -PAGE ）， gel method ， modified Ar⁃now. The efficacy of recombinant mussel adhesive protein was evaluated by cell migration and repairing effect of zebrafish tail fin. Re⁃sults showed that the obtained recombinant mussel adhesive protein was confirmed to be consistent with the theoretical primary structure ， protein purity of more than 95%， endotoxin <10 EU ·mg -1， DOPA content above 5%. When the recombinant mussel adhesive protein concentration was 60 μg ·mL -1， the effect of promoting cell proliferation was the most obvious ， and it had very significant activity （P <0.01）. The caudal fin area of zebrafish in sample group was significantly increased compared with model control group （P <0.001）. The results indicated that recombinant mussel adhesive protein can promote cell migration and repair healing and has the potential to be used as biomedical materials.Key words ：mussel adhesive protein ； gene recombination ； biological materials ； representation ； efficacy evaluation贻贝粘蛋白（mussel adhesive protein ， MAP ）也称作贻贝足丝蛋白（mussel foot protein ，Mfps ），收稿日期：2023⁃02⁃24； 接受日期：2023⁃03⁃31联系方式：李敏 E -mail:*******************;*通信作者 侯增淼 E -mail:***********************.cn李敏，等：重组贻贝粘蛋白的表征及功效评价是海洋贝类——紫贻贝（Mytilus galloprovincalis）、厚壳贻贝（Mytilus coruscus）、翡翠贻贝（Perna viri⁃dis）等分泌的一种特殊的蛋白质，贻贝中含有多种贻贝粘蛋白，包括贻贝粘蛋白（Mfp 1～6）、前胶原蛋白（precollagens）和基质蛋白（matrix proteins）等［1］。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-06-2018Print Date:Oct.-06-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Dabrafenib (Mesylate)Catalog No. :HY-14660ACAS No. :1195768-06-91.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Skin irritation (Category 2), H315Serious eye damage (Category 1), H318Respiratory sensitisation (Category 1), H334Skin sensitisation (Category 1), H317Germ cell mutagenicity (Category 2), H341Reproductive toxicity (Category 2), H361Specific target organ toxicity - single exposure (Category 1), H370Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335Chronic aquatic toxicity (Category 4), H4132.2 GHS Label elements, including precautionary statementsPictogramSignal word DangerHazard statement(s)H315: Causes skin irritation.H317: May cause an allergic skin reactionH318: Causes serious eye damage.H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.H335: May cause respiratory irritation.H341: Suspected of causing genetic defects.H361: Suspected of damaging fertility or the unborn child.H370: Causes damage to organs.H413: May cause long lasting harmful effects to aquatic life.Precautionary statement(s)P201: Obtain special instructions before use.P202: Do not handle until all safety precautions have been read and understood.P260: Do not breathe dust ⁄ fume ⁄ gas ⁄ mist ⁄ vapors ⁄ spray.P264: Wash skin thoroughly after handling.P270: Do not eat, drink or smoke when using this product.P271: Use only outdoors or in a well-ventilated area.P272: Contaminated work clothing should not be allowed out of the workplace.P273: Avoid release to the environment.P280: Wear protective gloves ⁄ eye protection ⁄ face protection.P302 + P352: IF ON SKIN: Wash with plenty of soap and water.P304 + P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.P305 + P351 + P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do.Continue rinsing.P310: Immediately call a POISON CENTER ⁄doctor.P321: Specific treatment (see supplemental first aid instructions on this label).P333 + P313: If skin irritation or rash occurs: Get medical advice ⁄ attention.P362: Take off contaminated clothing and wash before reuse.P403 + P233: Store in a well-ventilated place. Keep container tightly closed.P405: Store locked up.P501: Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:GSK-2118436 Mesylate;GSK2118436 Mesylate;GSK 2118436 Mesylate;GSK 2118436BFormula:C24H24F3N5O5S3Molecular Weight:615.67CAS No. :1195768-06-94. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 2Additional informationRTECS No.: DA8340700Alopecia., Liver injury may occur., Kidney injury may occur., Nausea, Headache, Vomiting, bone marrow depressionThis information is based on our current knowledge. However the chemical, physical, and toxicological properties have not been completely investigated.12. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 ComponentsNo chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 ComponentsNo chemicals in this material are subject to the reporting requirements of SARA Title III, Section 313.SARA 311/312 HazardsAcute Health Hazard, Chronic Health Hazard16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

益生菌对阿尔茨海默病作用的研究进展发布时间：2021-12-14T06:08:15.523Z 来源：《中国结合医学杂志》2021年12期作者：宋鑫萍1,2，李盛钰2，金清1[导读] 阿尔茨海默病已成为威胁全球老年人生命健康的主要疾病之一，患者数量逐年攀升，其护理的经济成本高，给全球经济造成重大挑战。

近年来研究显示，益生菌在适量使用时作为有益于宿主健康的微生物，在防治阿尔茨海默病方面具有积极影响，其作用机制可能通过调节肠道菌群，影响神经免疫系统，调控神经活性物质以及代谢产物，通过肠-脑轴影响该病发生和发展。

宋鑫萍1,2，李盛钰2，金清11.延边大学农学院，吉林延吉 1330022.吉林省农业科学院农产品加工研究所，吉林长春 130033摘要：阿尔茨海默病已成为威胁全球老年人生命健康的主要疾病之一，患者数量逐年攀升，其护理的经济成本高，给全球经济造成重大挑战。

近年来研究显示，益生菌在适量使用时作为有益于宿主健康的微生物，在防治阿尔茨海默病方面具有积极影响，其作用机制可能通过调节肠道菌群，影响神经免疫系统，调控神经活性物质以及代谢产物，通过肠-脑轴影响该病发生和发展。

本文综述了近几年来国内外益生菌对阿尔茨海默病的作用进展，以及其预防和治疗阿尔茨海默病的潜在作用机制。

关键词：益生菌；阿尔茨海默病；肠道菌群；机制Recent Progress in Research on Probiotics Effect on Alzheimer’s DiseaseSONG Xinping1,2，LI Shengyu2，JI Qing1*(1.College of Agricultural, Yanbian University, Yanji 133002，China)(2.Institute of Agro-food Technology, Jilin Academy of Agricultural Sciences, Chanchun 130033, China)Abstract：Alzheimer’s disease has become one of the major diseases threatening the life and health of the global elderly. The number of patients is increasing year by year, and the economic cost of nursing is high, which poses a major challenge to the global economy. In recent years, studies have shown that probiotics, as microorganisms beneficial to the health of the host, have a positive impact on the prevention and treatment of Alzheimer’s disease. Its mechanism may be through regulating intestinal flora, affecting the nervous immune system, regulating the neuroactive substances and metabolites, and affecting the occurrence and development of the disease through thegut- brain axis. This paper reviews the progress of probiotics on Alzheimer’s disease at home and abroad in recent years, as well as its potential mechanism of prevention and treatment.Key words：probiotics; Alzheimer’s disease; gut microbiota; mechanism阿尔茨海默病（Alzheimer’s disease, AD），系中枢神经系统退行性疾病，属于老年期痴呆常见类型，临床特征主要包括：记忆力减退、认知功能障碍、行为改变、焦虑和抑郁等。

β-拉帕醌分子量β-拉帕醌分子量β-拉帕醌（β-lapachone）是一种天然化合物，属于萘醌类化合物。

它具有广泛的生物学活性和药理特性，在癌症治疗和抗菌领域显示出潜在的应用价值。

本文将主要讨论β-拉帕醌的分子量以及其在药物研究中的重要性，以及一些相关的研究进展。

一、β-拉帕醌的分子量β-拉帕醌的分子式为C15H14O3，相对分子质量约为242.27 g/mol。

它是一种黄色结晶性固体，可以从南美的工厂树和美国的红杉中提取得到。

β-拉帕醌分子结构中包含一个萘环和一个醌环，具有独特的化学结构。

二、分子量在药物研究中的重要性1. 药物与分子量的关系分子量是用来描述物质的质量大小的一个重要指标。

在药物研究中，分子量不仅与药物的药理效应有关，还与药物的吸收、分布、代谢和排泄等参数有关。

2. 药物研发中的药物分子量筛选在药物研发的早期阶段，研究人员通常会根据目标疾病的特点以及药物的理化性质，设计分子量合适的化合物作为候选药物。

过大或过小的分子量可能会导致药效不佳或不稳定的问题。

3. 分子量与生物活性的关系研究表明，分子量对药物的生物活性有一定的影响。

一些研究发现，较低的分子量化合物通常具有更好的细胞渗透性和生物利用度，从而具有更高的药理活性。

三、β-拉帕醌在药物研究中的应用1. 抗肿瘤活性β-拉帕醌已被证明具有强烈的抗肿瘤活性。

它通过多种途径引起癌细胞凋亡，并且对多种肿瘤细胞株显示出选择性毒性作用，而对正常细胞的毒性较小。

因此，研究人员认为β-拉帕醌可能是一种潜在的抗癌药物。

2. 抗菌活性除了抗肿瘤活性外，β-拉帕醌还显示出一定的抗菌活性。

一些研究发现，β-拉帕醌对一些致病菌具有抑制作用，包括金黄色葡萄球菌和大肠杆菌等。

这为β-拉帕醌在抗菌领域的应用提供了一定的依据。

四、相关研究进展1. β-拉帕醌合成方法的改进为了提高β-拉帕醌的合成效率和产量，研究人员不断改进合成方法。

例如，一些研究利用催化剂和新颖的反应体系，成功地提高了合成β-拉帕醌的效率，并优化了工艺条件。

复美达（概述：）复美达是上海复旦张江生物医药股份有限公司研发一款针对鲜红斑痣等毛细血管瘤的光动力药物产品。

（表格）如下：中文名：复美达医学名：海姆泊芬英文名：Hemoporfin研究生产单位：上海复旦张江生物医药股份有限公司分类：化学药品第1.1类适应症：鲜红斑痣鲜红斑痣简介复美达（Hemoporfin）简介复美达（海姆泊芬）是上海复旦张江生物医药股份有限公司研发的一种新的单体卟啉光动力治疗药物，为一类创新药物。

海姆泊芬用于治疗鲜红斑痣、与年龄有关的黄斑病变及角膜血管增生等。

传统治疗方法主要是激光。

激光容易留下疤痕和反复。

一般每隔几个月就需要重新做激光。

复美达（光动力技术）是一种针对传统医治鲜红斑痣出现大量疤痕、肿胀、色素沉着、反复、费用高昂、避光期长等基础上，利用光动力技术在多领域、多临床经验的治疗新技术。

复美达进一步丰富了光动力技术的应用和临床，进一步丰富了光动力疗法。

复美达（海姆泊芬）治疗原理光动力治疗鲜红斑痣的原理为：光敏剂经静脉注射后立即在血液中形成浓度高峰，并被血管内皮细胞迅速吸收，而表皮层细胞吸收尚很少，因此光敏剂的分布在血管内皮细胞与表皮层细胞间形成明显的浓度差。

此时给予穿透表浅、可被血管内皮细胞选择性吸收的特定波长的激光照射，使光敏剂产生单态氧等光毒物质，使富含光敏剂的患部扩张畸形的毛细血管网被选择性破坏，而覆盖于扩张畸形毛细血管网上的正常表皮层因不含光敏剂不受损伤，位于扩张畸形毛细血管网下的正常真皮深层组织则因激光穿透浅、难以达到有效激发量而得到保护。

复美达特点海姆泊芬成分单一、结构明确；光动力治疗鲜红斑痣疗效显着，机理清晰；代谢迅速，避光期较短，不良反应轻；安全、有效、质量可控，是一种治疗鲜红斑痣的理想新药。

发展史2012年12月经国家食品药品监督管理总局（CFDA）批准，注射用海姆泊芬（国药证字H20120076）于获得新药证书。

专利名称：一种荜茇酰胺生物碱在制备治疗白癜风中促进黑色素生成的药物中的用途
专利类型：发明专利
发明人：李俊,阿布杜巴克耶夫·萨德尔别克,阿吉艾克拜尔·艾萨
申请号：CN201811284680.9
申请日：20181031
公开号：CN109364073A
公开日：
20190222
专利内容由知识产权出版社提供
摘要：本发明涉及一种荜茇酰胺生物碱在制备治疗白癜风中促进黑色素生成的药物中的用途，所述酰胺类生物碱类化合物为异胡椒碱、荜茇宁、假荜茇酰胺A和假荜茇酰胺C，并对其进行了小鼠黑色素瘤B16细胞中黑色素生成及酪氨酸酶活性的测定，结果表明：所述荜茇酰胺生物碱均能不同程度促进黑色素生成和酪氨酸酶活性，可用于制备治疗白癜风的药物。

为治疗白癜风的药物开发提供了有利物质基础。

申请人：中国科学院新疆理化技术研究所
地址：830011 新疆维吾尔自治区乌鲁木齐市北京南路40号附1号
国籍：CN
代理机构：乌鲁木齐中科新兴专利事务所(普通合伙)
代理人：张莉
更多信息请下载全文后查看。

分子量615.67溶解性（25°C）DMSO 44 mg/mL分子式C H F N O S.CH O S Water <1 mg/mLCAS号1195768-06-9Ethanol <1 mg/mL储存条件3年 -20°C 粉末状生物活性Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，IC50为0.8 nM，作用于B-Raf(wt)和c-Raf效果低4和6倍。

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。

Dabrafenib抑制B-Raf激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-Raf的癌细胞中细胞停滞在G1期。

Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。

实验操作来自于公开的文献，仅供参考细胞实验细胞系A375P, SKMEL28 and Colo205 cell lines方法A375P-F11 assay: A375P cells were plated in 96-well plates by limiting dilution and single cell-derived clones were harvested and tested for sensitivity to B-Raf inhibitors. The F11 clone was selected for future studies and was named A375P-F11. Cellular pSmadAssay to Measure Anti-TGF-β Activity: Activity of compounds was tested in a mechanistic assay in HepG2 cells. Cells were seeded in12-well plates at a density of 500,000 cells/well and allowed to adhere overnight at 37℃/5% CO2. Media (BME+10% serum) wasremoved and compound in serum free media was added to the cells for 45 minutes at 37oC/5% CO2. Cells were stimulated with 1ng/ml TGF-β (R&D systems) for 60 minutes. Cells were lysed in buffer (25 mM Tris-HCl ph: 7.5, 2 mM EDTA, 2 mM EGTA,1% Triton X-100, 0.1 % SDS, 50 mM sodium-β-glycerophosphate, 2 mM sodium orthovanadate, 12.5 mM sodium pyrophosphate, protease andphosphatase inhibitor cocktails) for 30 minutes, scraped, collected, clarified by centrifugation and prepared for western blots inLDS/reducing reagent (Invitogen). Samples were resolved on 4-12% Bis-Tris gels, transferred to PVDF, and probed for total andphospho-Smad2 using antibodies from Cell Signaling. Gels were imaged using the odyssey blot scanner (Licor) and quantified usingLicor software. Phospho:total Smad2 ratios were determined and the IC50 was defined as the concentration of compound whichdecreased the phospho:total ratio by 50%.浓度0~10 nM处理时间动物实验动物模型A375P F11 Melanoma Xenograft in nude mice配制0.5% hydroxypropylmethylcellulose (Sigma) and 0.2% Tween-80 in distilled water pH 8.0剂量0.2 mL/20g daily给药处理oral gavage不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）小鼠大鼠兔豚鼠仓鼠狗重量 (kg)0.020.15 1.80.40.0810体表面积 (m)0.0070.0250.150.050.020.5K系数36128520 Dabrafenib Mesylate 目录号M1855化学数据2320352243V600E V600E2m动物 A (mg/kg) = 动物 B (mg/kg) ×动物 B 的K 系数动物 A 的K 系数例如，依据体表面积折算法，将白藜芦醇用于小鼠的剂量22.4 mg/kg 换算成大鼠的剂量，需要将22.4 mg/kg 乘以小鼠的K 系数（3），再除以大鼠的K 系数（6），得到白藜芦醇用于大鼠的等效剂量为11.2 mg/kg 。

紫杉醇胶束英文说明书译文Paclitaxel Powder for injection专属mPEG-PDLLA高分子胶束聚合物Composition（组成）：Genexol PM规格：30mg/瓶或100mg/瓶赋形剂：q.sDescription（处方）Genexol PM是水溶性紫杉醇高分子聚合物，这种高分子胶束纳米技术可免去了紫杉醇普通制剂中蓖麻油的毒性。

Genexol PM 为白色或黄色的冻干粉粉末Indication（适应症）：转移或复发性乳腺癌的一线用药Dosage and Administration（用法用量）乳腺癌：推荐剂量300mg/m2，静滴3h，1次/3W。

Premedication（预防用药）Genexol PM不要求预防过敏反应的预防给药；但为了尽量减低严重可能发生的过敏反应或根据医生的意见，能够考虑在给予Genexol PM前30min，进行预防用药，包括：氢化可的松100mg iv（或其同类药物），马来酸非尼拉敏45.5mg iv（或其同类药物），西咪替丁300mg或雷尼替丁50mg iv（或其同类药物）。

Dose Adjustment（剂量调整）接受Genexol PM治疗的患者，可根据其毒性反应调整给药剂量（见表1）。

如果患者在降低剂量至Level-2水平后仍不能耐受，需考虑停药。

表1. 乳腺癌患者剂量调整指导原则First dose adjustment（240mg/m2）：患者出现中性粒细胞减少性发热或严重的中性粒细胞减少（<500个/mm3）或血小板减少（<50000个/mm3）持续一周及以上，应考虑调整剂量至Level-1；如果患者出现3级的中性粒细胞相关的毒性，应降低剂量至Level-1；如果患者出现4级的中性粒细胞相关的毒性，应考虑停药。

Second dose adjustment（190mg/m2）：如果患者在Level-1剂量时，以上毒性再次出现，应该降低剂量至Level-2。

增强型DAB显色试剂盒（20×）说明书货号：DA1015规格：3ml×3/10ml×3试剂盒内容：DA1015-3DA1015-10溶液A3ml10ml溶液B3ml10ml溶液C3ml10ml保存：-20℃避光密闭保存，复检期至少1年。

产品简介：增强型DAB显色试剂盒是一种借助辣根过氧化物酶(HRP)，用于免疫组化显色、原位杂交显色或Western、Southern、Northern、EMSA等膜显色的试剂盒。

DAB是辣根过氧化物酶的常用底物。

在辣根过氧化物酶的催化下，DAB会产生棕色沉淀。

该棕色沉淀不溶于水和乙醇。

操作说明：1.对于组织切片或蛋白质印记膜，在与辣根过氧化物酶（HRP）标记的抗体或其它形式的探针孵育后，用适当洗涤液洗涤3-5次，每次3-5分钟。

2.向4.25ml蒸馏水中加入250μl溶液A、250μl溶液B、250μl溶液C，并混合均匀，即为DAB 工作液，1h内使用。

注意：溶液A/B/C必须完全融化后使用。

3.向组织切片或膜上加入适量DAB工作液，确保能充分覆盖样品。

4.室温避光孵育1-30分钟，显色时间过长可引起本底增高，故应密切观察显色过程（一般3-10分钟最理想），并在本底较浅且达到适当显色强度时以流水漂洗终止显色反应。

5.对于组织切片或细胞样品，显色反应终止后可对其进行其他染料复染。

对于膜，显色反应终止后，可以室温晾干避光保存。

注意事项：1．DAB溶液应低温密封保存。

如有结晶析出，应确保结晶完全溶解再行使用；2．显色工作液应现用现配，新鲜配制的工作液应为无色或浅棕色，如颜色过深，请勿使用；3.DAB在常温下不稳定，每次取用后均应及时加盖密封放回冰箱，以免因DAB分解影响实验，或因渗漏造成实验环境污染。

4.DAB有潜在致突变作用，操作时应注意穿戴好防护用具。

5.DAB溶液C成分为H2O2,该组分易降解，必要时可自行配备。